March 19, 1999 Re Intracellular Assays - Final Comments At the risk of ending up like Alexander Hamilton, I will add my final comments to the debate I unwittingly started. Waxy raised some points which are very relevant. Intracellular assays are becoming common in clinical diagnosis of leukemia/lymphoma (markers like MPO, CD3, CD22, CD79a, TdT, Ig etc). My experience is that these assays are predominantly done with commercial permeabilization kits. There are several sciebtific publications comparing the various kits. Practically, a clinical lab is not likely to use (and validate) home brew reagents when commercial kits are available, given the regulatory environment The same issues potentially apply to intracellular cytokine assays. If they are going to ultimately be useful clinically, standardized, commercial reagents will have to be available. Ideally, they will have the validation and support of the scientific community. It seems to me we should be working in harmony rather than in a confrontational mode. Bob Johnson Caltag Laboratories
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:53:17 EST